RA
PEAR

RiverPark Advisors’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

RiverPark Advisors’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,304,598
Closed -$13M – 243
2021
Q3 		$13M Hold
1,304,598
– – 1.58% 24
2021
Q2 		$12.9M Buy
+1,304,598
New +$12.8M 1.65% 25

Other funds holding PEAR

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SGA
SB Global Advisers London, United Kingdom $861M AUM 71.72% 1-Year Est. Return
AV
Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

RiverPark Advisors's PEAR Position: Q4 2021 in Review

RiverPark Advisors sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q4 2021, closing a stake of 1,304,598 shares — an estimated $13M sold.

RiverPark Advisors first reported a position in PEAR in Q2 2021 and held it in 2 quarters. The position peaked at $13M in Q3 2021. 25 funds tracked by Wall St. Rank hold PEAR as of Q4 2021.

  • RiverPark Advisors reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
  • RiverPark Advisors sold 1,304,598 Pear Therapeutics, Inc. Class A Common Stock shares in Q4 2021, an estimated $13M.
  • RiverPark Advisors first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q2 2021 and held it in 2 quarters.
  • RiverPark Advisors's Pear Therapeutics, Inc. Class A Common Stock position peaked at $13M in Q3 2021.
  • 25 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q4 2021.

Based on RiverPark Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.